Nuvectis Pharma (NVCT) Net Cash Flow (2021 - 2026)

Nuvectis Pharma has reported Net Cash Flow for 6 years, with the latest figure at -$6.5 million in Q1 2026.

• Quarterly Net Cash Flow fell 157.4% year-over-year to -$6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.7 million (down 145.52% YoY) and the FY2025 annual result came in at $13.1 million, up 2309.27% from the prior year.
• Net Cash Flow retreated to -$6.5 million in Q1 2026 per NVCT's latest filing, from -$3.8 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $11.3 million in Q1 2025 and troughed at -$6.5 million in Q1 2026.
• A 5-year average of $1.1 million and a median of -$1.3 million in 2024 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 3252.37% in 2025, down 379.18% in 2025.
• Over 5 years, Net Cash Flow stood at -$3.6 million in 2022, then climbed by 19.58% to -$2.9 million in 2023, then soared by 146.51% to $1.4 million in 2024, then plunged by 379.18% to -$3.8 million in 2025, then tumbled by 70.8% to -$6.5 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$6.5 million, -$3.8 million, and $8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.